Related Experiment Videos
GM-CSF-based cancer vaccines
1Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. glenn_dranoff@dfci.harvard.edu
Abstract:
The crafting of genetic and biochemical techniques to identify cancer antigens yielded the unexpected discovery that immune recognition of tumors regularly accompanies cancer development. The failure of the host to suppress tumor formation or attenuate disease progression may thus reflect the limited immunogenicity of nascent tumors. One critical determinant of host immunity is the mixture of cytokines produced in the tumor microenvironment. We have compared a large number of secreted and surface molecules for their relative abilities to augment tumor immunity following gene transfer into cancer cells. In multiple murine models, granulocyte-macrophage colony stimulating factor (GM-CSF) proved to be the most potent immunostimulatory product. Vaccination with irradiated tumor cells engineered to secrete GM-CSF involves enhanced tumor antigen presentation by recruited dendritic cells (DCs) and macrophages; the coordinated functions of CD4+ and CD8+ T cells, CD1d-restricted NKT cells and antibodies mediate protective immunity. The evaluation of this vaccination strategy in patients with advanced melanoma revealed the consistent induction of cellular and humoral antitumor responses capable of effectuating substantial necrosis of distant metastases. The formulation of simplified methods for manufacturing autologous, GM-CSF-secreting tumor cells has enabled more extensive clinical testing in diverse patient settings.
Insights
Cancer vaccines engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively stimulate immune responses against tumors. This approach shows promise in treating advanced melanoma by inducing antitumor immunity and causing metastasis necrosis.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumor immune recognition is crucial for cancer development.
- Limited tumor immunogenicity hinders host suppression of cancer.
- Cytokines in the tumor microenvironment significantly impact host immunity.
Purpose of the Study:
- To identify molecules that enhance tumor immunity via gene transfer into cancer cells.
- To evaluate the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunostimulatory agent.
- To assess a novel cancer vaccination strategy in preclinical models and advanced melanoma patients.
Main Methods:
- Gene transfer of various molecules into cancer cells for comparative analysis.
- Utilizing multiple murine models to test tumor immunity augmentation.
- Administering GM-CSF-secreting tumor cell vaccines to patients with advanced melanoma.
- Assessing cellular and humoral antitumor responses and clinical outcomes.
Main Results:
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) was identified as the most potent immunostimulatory product.
- GM-CSF secreting tumor cell vaccination enhanced antigen presentation by dendritic cells and macrophages.
- Vaccination induced coordinated immune responses involving T cells, NKT cells, and antibodies, leading to protective immunity.
- Clinical evaluation in advanced melanoma patients demonstrated consistent induction of antitumor responses and significant metastasis necrosis.
Conclusions:
- GM-CSF secreting tumor cell vaccination is a potent strategy for augmenting antitumor immunity.
- This approach effectively overcomes limited tumor immunogenicity and promotes tumor regression.
- Simplified manufacturing of autologous GM-CSF secreting tumor cells facilitates broader clinical application.
- The findings support further clinical investigation of GM-CSF based cancer vaccines in various patient populations.